|
Cytos says allergy drug meets main target in study
Reuters ZURICH, July 31 (Reuters) – An allergy treatment from Swiss biotech company Cytos (CYTN.S) met its main target in a mid-stage trial, the group said on … DGAP-News: Cytos Biotechnology AG: CYT003-qbg10 monotherapy for …Ad-Hoc-News (Pressemitteilung) all 5 news articles » |